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Abstract
During the last decades the advance in knowledge of myofascial pain has been constant in the medical and dental 
community. However, although several aspects have been clarified in relation to its epidemiology, clinical charac-
teristics and etiopathogenesis, many uncertainties remain. Many clinical conditions are included in the differential 
diagnosis of myofascial pain associated to trigger points. A good anamnesis and clinical exploration is thus re-
quired in order to ensure correct diagnosis and treatment. Among the numerous treatments used in application to 
trigger points, the spray-and-stretch technique and direct injection targeted to such trigger points have been found 
to be the most effective options. In chronic cases, psychosocial intervention is required, due to the high incidence 
of mood disorders and/or anxiety observed in these patients, who in turn present a poorer prognosis. This under-
scores the importance of early diagnosis and treatment.
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Introduction
Myofascial pain associated to trigger points (TPs) has 
been investigated by the medical and dental community 
for over a century. However, different aspects relating 
to its physiopathology, clinical presentation and treat-
ment remain to be clarified (1,2).
It has been difficult to establish diagnostic criteria and 
specific treatment protocols for myofascial pain syn-
drome, since most studies to date have grouped patients 
with different musculoskeletal disorders, due to a lack 
of consensus over the corresponding screening criteria 
(1). The present study describes myofascial pain based 
on the main characteristics reported in the literature re-
garding the differential diagnosis and treatment of this 
disorder.
Differential Diagnosis
A range of disorders have been included in the differen-
tial diagnosis of myofascial pain (Table 1) (3,4), though 
fibromyalgia, cervical joint dysfunction, non-myofas-
cial trigger points and post-traumatic hyperirritability 
syndrome (PHS) are the conditions most often wrongly 
diagnosed as myofascial pain (4). 
Fibromyalgia (FM) is a chronic disease characterized 
by pain in multiple body locations and generalized 
tiredness. It is a common disorder, found in 1-3% of the 
general population (5,6), and can manifest as a single 
disorder (primary fibromyalgia) or associated to other 
illnesses (concomitant fibromyalgia). In this context, fi-
bromyalgia may be concomitantly present in over 50% 
of all patients with myofascial pain associated to TPs 
(7). 
Some theories have implicated alterations in neurotrans-
mitter regulation, immune function, sleep physiology or 
hormonal control in the pathogenesis of fibromyalgia – 
all associated to dysfunction of the limbic system and 
neuroendocrine axis (5,8,9).
It is necessary to distinguish the painful points of fibro-
myalgia from the TPs of myofascial pain, since activa-
tion of the latter causes referred pain and central exci-
tation phenomena, whereas stimulation of the painful 
points in fibromyalgic patients does not produce such 
symptoms (Table 2) (4-7).
Non-myofascial TPs can be located in skin, tendons, 
fascias, scars and ligaments, and can induce referred 
pain phenomena similar to those described in myofas-
cial pain. In both cases the proposed treatment is the 
same, though there is no evidence of any kind that the 
referred pain patterns of non-myofascial TPs are analo-
gous to those found in patients with myofascial pain. 
An important difference between the two diseases is the 
absence of palpable hypersensitive nodules in the non-
myofascial TP zones (1-3).
Post-traumatic hyperirritability syndrome (PHS) is 
found in a limited group of patients with myofascial 
pain, where important sensory irritability is observed as 
a result of severe head and neck injuries (generally due 
to traffic accidents). The pain in these subjects tends 
to be constant, though they may present an increase 
in motor activity as a result of the loss of supraspinal 
inhibition, giving rise to muscle spasms in response to 
any intense sensory stimulus. PHS can be mistakenly 
diagnosed as a psychological disorder on the basis of the 
absence of organic alterations capable of accounting for 
the symptoms (3,10).
Joint dysfunction represents one of the musculoskeletal 
pain syndromes that most often produce muscle pain 
(3,7). In this case the increase in muscle tension and ac-
tivity associated to TPs can perpetuate or provoke joint 
stress, while in some cases joint stress can cause TP ac-
tivation. Thus, joint treatment of the joint and muscle 
disorders is essential if both conditions are assumed to 
coexist (3).
Treatment
The spray-and-stretch technique and punction-injection 
of the TPs constitute the treatment modalities of choice, 
in view of their efficacy in eliminating the TPs (1,2,11).
Non-myofascial trigger point (fibromyal-a) 
gia)
Musculoskeletal diseases: b) 
Temporomandibular joint disorders- 
Occupational myalgias- 
Post-traumatic hyperirritability syndrome- 
Joint dysfunction (osteoarthritis)- 
Tendonitis and bursitis- 
Neurological disorders: c) 
Trigeminal neuralgia- 
Glossopharyngeal neuralgia- 
       -       Sphenopalatine neuralgia
Systemic diseasesd) 
Rheumatoid arthritis- 
Gout- 
Psoriatic arthritis- 
Infections (viral, bacterial and/or proto-- 
zoan)
Heterotopic pain of central origine) 
Axis II-type disorders:f) 
Psychogenic pain - 
Painful behaviors- 
Drug reactionsg) 
Table 1. Clinical conditions included in the differential diag-
nosis of pain trigger points (3,4).
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The spray-and-stretch technique allows treatment of an 
extensive anatomical territory, favoring the simultaneous 
recovery of several muscles (2,12). The objective is to 
cool the muscle in its entire extent by applying a vapo-
rized cooling liquid, followed by passive stretching of 
the treated muscle (2). 
In this context fluori-methane is the vaporized coolant 
of choice for the treatment of myofascial pain, since it is 
noninflammable, chemically stable and not toxic for the 
patient. However, the negative environmental impact of 
this agent has led to the search for alternatives (2). 
Most authors recommend placing the vaporizer at a dis-
tance of about 45 cm from the skin, and at an angle of 30 
degrees (1,2,4). The vaporizing substances are applied 
as a fine stream or jet, since efficacy in spray form is 
limited. The jet is directed in a single direction (cau-
dad to cranial) towards and including the affected zone. 
Once the treatment has been applied, relative rest of 
the treated zones is advised for two or three days, with 
muscle stretching and strengthening exercises (isotonic 
and isometric). The application of warmth with a cloth 
is advised at the end of each vaporizing cycle (2). 
The inactivation of myofascial TPs through the injec-
tion of local anesthetics is one of the most important 
management options. The mechanism of action is based 
on the disruption and inactivation of the active “locus” 
of the TP (1, 12-14). Local anesthetics are used only for 
reducing the post-injection pain that usually accompa-
nies injection of the TPs (13,14). Some authors prefer 
the “dry” puncture technique, since the use of local 
anesthetics complicates the location of TPs adjacent to 
the injection zone (12). Most studies have shown no sta-
tistically significant differences between injection with 
local anesthetic and the “dry” puncture technique in 
eliminating TPs (11,15), and Kamanli et al. (13) have 
even concluded that the latter is more effective and fast-
er acting than anesthetic inoculation.
Procaine is the local anesthetic offering the best results 
in infiltrating TPs (2,3). Its main advantages are short 
action (15-20 minutes) and minimal systemic toxicity, 
with the absence of local irritation. Other local anes-
thetic agents such as lidocaine, prilocaine, mepivacaine 
and bupivacaine (1,12, 16-18), and more recently also 
levobupivacaine and ropivacaine (15), have been cited 
TRIGGER POINTS TENDER POINTS
Gender distribution 1:1 4-9 females:1 male
Physical character-
istics
Muscular, tense bands, referred 
pain, reproducible pain, irritability
Tender areas in muscles, tendons, liga-
ments, joint capsules
Distribution Focal-asymmetrical. Located in any muscle
Generalized-symmetrical. Concrete loca-
tions
Pain pattern
Regional pain
Focal tenderness 
Generalized pain
Generalized tenderness
Skin fold sensitivity Not known Often present
Mobility Restricted movement range Hypermobility
Histology No specific changes in biopsy No specific changes in biopsy
Palpation Rigid muscle palpation (palpable nodules) Soft and flaccid muscle palpation
Algometry Threshold 2 kg/cm² over adjacent normal zones 4 kg pressure
Reliability index Good in pain in response to palpa-tion and with algometry; poor in rest Good in relation to pain or algometry
MRI findings No data No morphological changes
Electromyography Spontaneous activity at trigger points 1 or 2 mm
No denervation
No muscle spasm
Allodynia / hyperal-
gesia Only present at trigger points At tender points and other control sites
Treatment with local 
injection Immediate response to injections Poor response to injections
Comorbidity 20% have fibromyalgia 72% have active trigger points
Table 2. Differences and similarities between trigger points and tender points (4-7).
Med Oral Patol Oral Cir Bucal. 2010 Jul 1;15 (4):e639-43.                                                                                                                                                                                                Myofascial pain
e642
in the literature for the management of myofascial pain. 
The ideal local anesthetic concentration is 0.5%, since 
higher concentrations do not afford significant thera-
peutic advantages (2,13,16). Local anesthetic infiltra-
tion is always carried out without a vasoconstrictor, and 
the use of bisulfite in the anesthetic preparation is to 
be avoided, since it causes post-injection sensitivity and 
pain (2,18).
The anesthetic solution can be replaced in the injection 
solution by corticosteroids, nonsteroidal antiinflamma-
tory drugs and/or type A botulin toxin (12,13,15,16,19), 
though the latter is exclusively used in patients who are 
resistant to the conventional treatment (20). 
During TP injection it is advisable to place the patient 
in a reclined position, to avoid the appearance of va-
sovagal syndrome (2,12). It is essential to apply a local 
antiseptic (alcohol, povidone iodine, etc.) in the muscle 
zone before injection, and injection or puncture in areas 
with skin or muscle infection or susceptible to infection 
must be avoided (2). 
The needles used are of gauges 21 and 22, with a length 
of 7.6 cm, though a 25 gauge needle is preferred in very 
painful zones or in patients with capillary fragility. The 
needle is to be inserted no more than two-thirds of its 
length, in order to avoid the risk of fracture in the event 
of sudden movement (2,12). The traditional TP injection 
technique involves firming or tensing the skin at the in-
jection site and inserting the needle perpendicular to the 
surface of the skin (2).
After the injection, the local and referred pain decrea-
ses for a period of approximately 7 days, after which 
it gradually increases again - though without reaching 
the initial intensity before treatment. As a result, several 
sessions are needed to achieve lasting effects (2,11,13). 
The appearance of ecchymosis and inflammation after 
injection is common. Damage to important structures 
surrounding the injection site is infrequent, provided 
we have good anatomical knowledge of the zone. Dama-
ge to nerve endings is uncommon – thereby limiting the 
risk of motor or sensory alterations. TP treatment with 
local injections or puncture is absolutely contraindicat-
ed in patients subjected to anticoagulant therapy, and 
special precautions are required in smokers (2,21). 
However, Shen et al. (22) have suggested that pain re-
duction in the treatment of TPs as a result of nociceptive 
stimulation is not dependent upon the location of the 
stimulus but on the stimulus itself. In any case, Tough 
et al. (14) have indicated that the heterogeneity of the 
studies published to date does not allow the drawing of 
significant conclusions regarding the effectiveness of 
puncture therapy versus placebo.
The terms “ischemic compression” and “myotherapy” 
have been used to describe treatment in which ischemia 
is induced in the TP zone by applying sustained digital 
pressure. However, this principle is rather meaning-
less, since the nucleus of the trigger point intrinsically 
presents important hypoxia (2,3). 
Simons et al. (2) described a similar treatment modality, 
though without the need to induce additional ischemia 
in the TP zone. The aim of this technique is to free 
the contracted sarcomeres within the TP. The amount 
of pressure applied should suffice to produce gradual 
relaxation of the tension within the TP zone, without 
causing pain. Some authors suggest that certain forms 
of acupuncture (shiatsu) have analogies with this treat-
ment modality (14). Deep massage may prove effective 
in eliminating TPs when performed by experienced 
professionals. In this context, it is the most effective 
manual method in the treatment of myofascial pain. It 
therapeutic principle is similar to that of the sustained 
pressure technique (2,17,23).
Ultrasound, iontophoresis, phonophoresis and high-
voltage galvanic stimulation are used by many profes-
sionals for the treatment of myofascial pain, though none 
of these techniques are supported by scientific evidence 
of their efficacy in eliminating TPs. As such, they are 
regarded as coadjuvant therapies (2, 24-26). In the same 
way, transcutaneous electric nerve stimulation (TENS), 
drug treatment and/or cryo-thermotherapy are only use-
ful for controlling the pain symptoms that accompany 
myofascial pain (27). Nevertheless, the effectiveness 
of these techniques tends to decrease in the treatment 
of chronic myofascial pain (17). At present, low-power 
laser irradiation has been proposed for the treatment of 
TPs, though the results obtained have not been superior 
to those recorded in the placebo group (28).
The administration of nonsteroidal antiinflammatory 
drugs is of some use in controlling post-injection pain 
in the context of TP therapy (2,3,12). The use of muscle 
relaxants in the management of musculoskeletal diseas-
es has been based on the wrong conception that mus-
cle pain induces spasms in the affected muscle tissue. 
In this context, normal electromyographic activity has 
been demonstrated in patients with muscle pain – thus 
invalidating the above idea (1,29).
The administration of antihistamines, tricyclic antide-
pressants and natural hormones such as melatonin is 
recommended in myofascial pain characterized by the 
presence of sleep disturbances (2). The consumption of 
alcohol, caffeine and nicotine is contraindicated in pa-
tients of this kind, since these substances can worsen 
the symptoms of myofascial pain by inducing sleep dis-
turbances and increased sympathetic activity (1-3, 21). 
Vignolo et al. (30) have reported that oral contraceptive 
use is associated to lesser pain levels in patients with 
TPs, though the reason for such a reduction in pain was 
not commented.
The prognosis of myofascial pain is directly related to 
the duration of the condition. As a result, an early diag-
nosis is fundamental. In general, acute muscle injuries 
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with defined etiological factors offer a favorable prog-
nosis, provided they are treated in time. Patients with 
referred pain that proves stable over time and without 
spread to adjacent muscles respond better to treatment 
than patients with progressive worsening of their symp-
toms (1-3). In any case, and regardless of the treatment 
administered, it is necessary to eliminate as many per-
petuating factors as possible, provide adequate postural 
instructions for the patients, and prescribe an exercise 
program to be carried out at home, with a view to redu-
cing or eliminating the chronic pain (17,23).
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